共 50 条
Extracellular vesicles for the treatment of central nervous system diseases
被引:48
作者:
Gratpain, Viridiane
[1
]
Mwema, Ariane
[1
,2
]
Labrak, Yasmine
[1
,2
]
Muccioli, Giulio G.
[2
]
van Pesch, Vincent
[3
,4
]
des Rieux, Anne
[1
]
机构:
[1] Catholic Univ Louvain, Louvain Drug Res Inst, Adv Drug Delivery & Biomat, UCLouvain, B-1200 Brussels, Belgium
[2] Catholic Univ Louvain, Louvain Drug Res Inst, Bioanal & Pharmacol Bioact Lipids, UCLouvain, B-1200 Brussels, Belgium
[3] Catholic Univ Louvain, Inst Neurosci, Neurochem Unit, UCLouvain, B-1200 Brussels, Belgium
[4] Clin Univ St Luc, B-1200 Brussels, Belgium
关键词:
miRNA;
Nose to brain;
Glioblastoma;
Neurodegeneration;
Neuroinflammation;
Surface modification;
Nanocarriers;
Drug Delivery;
Multiple Sclerosis;
BLOOD-BRAIN-BARRIER;
MESENCHYMAL STROMAL CELLS;
CONVECTION-ENHANCED DELIVERY;
DRUG-DELIVERY;
ALPHA-SYNUCLEIN;
IN-VITRO;
PARKINSONS-DISEASE;
ENDOTHELIAL MICROPARTICLES;
ALZHEIMER-DISEASE;
MEDIATED TRANSFER;
D O I:
10.1016/j.addr.2021.05.006
中图分类号:
R9 [药学];
学科分类号:
1007 ;
摘要:
The interest in extracellular vesicles (EVs) increased during the last decade. It is now established that these vesicles play a role in the pathogenesis of central nervous system diseases (CNS), which explains why they are studied as biomarkers in these pathologies. On the other hand, EVs can also present ther-apeutic properties, often similar to their parent cells, as observed with mesenchymal stem cell-derived EVs. They can then be used as therapeutics, alone or combined with a bioactive molecule, for the treat-ment of CNS diseases, as they can cross the blood-brain barrier more easily than synthetic nanomedici-nes and are less immunogenic. A few clinical trials are currently on-going but there are still challenges to overcome for further clinical translation such as the scale-up of the production, the lack of standardiza-tion for isolation and characterization methods and the low encapsulation efficiency. (c) 2021 Elsevier B.V. All rights reserved.
引用
收藏
页码:535 / 552
页数:18
相关论文